$34.03
1.22% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US45258J1025
Symbol
IMVT

Immunovant Inc Stock price

$34.03
+6.18 22.19% 1M
+0.97 2.93% 6M
-8.10 19.23% YTD
+11.01 47.83% 1Y
+25.02 277.69% 3Y
+24.13 243.74% 5Y
+24.08 242.01% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.41 1.22%
ISIN
US45258J1025
Symbol
IMVT
Sector

Key metrics

Market capitalization $4.98b
Enterprise Value $4.42b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 9.13
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-298.51m
Free Cash Flow (TTM) Free Cash Flow $-243.55m
Cash position $560.01m
EPS (TTM) EPS $-1.92
P/E forward negative
Short interest 19.11%
Show more

Is Immunovant Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Immunovant Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Immunovant Inc forecast:

15x Buy
100%

Analyst Opinions

15 Analysts have issued a Immunovant Inc forecast:

Buy
100%

Financial data from Immunovant Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.55 0.55
59% 59%
-
-0.55 -0.55
59% 59%
-
- Selling and Administrative Expenses 60 60
22% 22%
-
- Research and Development Expense 238 238
22% 22%
-
-298 -298
22% 22%
-
- Depreciation and Amortization 0.55 0.55
59% 59%
-
EBIT (Operating Income) EBIT -299 -299
21% 21%
-
Net Profit -273 -273
11% 11%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunovant Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunovant Inc Stock News

Positive
Seeking Alpha
about one month ago
In the first half of 2024, our long book performed strong relative to the Russell 2000, driven by our high-conviction positions. We are pleased with our relative performance and believe the Russell 2000 remains a more appropriate benchmark for comparison. Top gainers include FTAI Aviation and FTAI Infrastructure, while top detractors include Latch and Industrial Short.
Negative
Investors Business Daily
3 months ago
Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."
More Immunovant Inc News

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.

Head office United States
CEO Peter Salzmann
Employees 207
Founded 2018
Website www.immunovant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today